Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

NovoCodex Acquires China Rights to Second Ambrx ADC Candidate

publication date: Oct 23, 2019

NovoCodex Biopharma of Shanghai acquired China rights to an antibody drug conjugate aimed at CD70 positive cancers from San Diego's Ambrx. The candidate targets renal cell cancers and melanoma. Previously, NovoCodex in-licensed rights to an Ambrx ADC for HER2 positive cancers. NovoCodex, a majority owned subsidiary of Zhejiang Medicine, will fund global development of ARX305 through Phase I clinical trials. It will also make an upfront payment along with development milestones and double digit royalties, though it will be eligible to receive an undisclosed share of ARX305 sales outside of China. More details....

Stock Symbol: (SHA: 600216)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.